Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced breast cancer: experimental drug combo enters trials

NCT ID NCT07560124

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen May 02, 2026 · Last updated May 22, 2026 · Updated 5 times

Summary

This study tests an experimental drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 with measurable tumors and adequate organ function may join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

    Contact

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

    Contact

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

    Contact

Conditions

Explore the condition pages connected to this study.